Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That is a lucrative number ;)
It's a Chinese company...maybe google whatever the translation is. Probably they just haven't had enough going on to be written about much in English.
If they were planning to dilute why wouldn't they have done it on previous good news before the restricted shares became eligible to be sold?
"..the Company will be well positioned to continue to capitalize on the enormous potential of the Chinese market, while avoiding significant capital commitments."
I would think they'll do pretty well if they can sign more licensing agreements like this that don't require them putting up much capital.
I'm hoping to hear something soon about the uplisting to OTCBB and about initial license revenues from India which are expected soon.. I would hope that CCTC would release whatever news they have since they've obviously been anticipating this decline for over a year now once the restricted shares became available to sell.
Nice ;)
I would expect they'd have opportunity for more contracts in China considering they're apparently expected to add about 200 more coal plants over the next few years:
http://www.export.gov/articles/successstories/eg_main_017203.asp
I'm hoping people won't bother selling so low if they do hold restricted shares since apparently in order to sell you need to first hire a securities lawyer..
http://www.cleancoaltechnologiesinc.com/index.php?option=com_content&task=view&id=2&Itemid=3
From the Dept. of Energy website:
"President Obama announced a Presidential Memorandum (linked below) creating an Interagency Task Force on Carbon Capture and Storage to develop a comprehensive and coordinated federal strategy to speed the development and deployment of clean coal technologies. Our nation’s economy will continue to rely on the availability and affordability of domestic coal for decades to meet its energy needs, and these advances are necessary to reduce pollution in the meantime. The President calls for five to ten commercial demonstration projects to be up and running by 2016."
http://www.energy.gov/news/8596.htm
"Rapid commercial development and deployment of clean coal technologies, particularly carbon capture and storage (CCS), will help position the United States as a leader in the global clean energy race."
http://www.whitehouse.gov/the-press-office/presidential-memorandum-a-comprehensive-federal-strategy-carbon-capture-and-storage
Does anyone have an idea about when/if this will be uplisted to to the otcbb? This was put out last Oct.:
Mr. Hague stated, "We are very pleased to have achieved this important milestone, which now paves the way for the Company to seek a market maker to make an application on our behalf to have CCTC's common stock quoted on FINRA's over-the-counter bulletin board ('OTCBB'). Having completed this monumental task, we truly believe that we are in an excellent position to take our company to the next level."
http://www.cleancoaltechnologiesinc.com/index.php?option=content&task=view&id=35
Thanks ;)
Thanks. I also found this (unofficial) website that says CCTC has its own assigned representative from the U.S. Department of Commerce?
http://www.cleancoaltechnologies.info/index.html
From the U.S. Commerce Dept. website:
"The deal between Clean Coal Technologies, Inc. (CCTI) of Coral Springs, Fla., and Shanxi POAR Environmental in China represents some of the most advanced clean coal technology in the world to be sold to China."
http://www.export.gov/articles/successstories/eg_main_017203.asp
Here's an interesting older article (from 8/8) about CCTC:
http://www.powergenworldwide.com/index/display/articledisplay/335142/articles/power-engineering/volume-112/issue-7/features/export-markets-for-us-clean-coal-technology.html
"The first plant in Shanxi, China’s largest coal mining province, is expected to be outfitted by late 2009. The agreement, estimated at $100 million for the first coal plant, is expected to lead to additional sales of this clean coal technology..."
Nice....Thanks. Apparently that's an appropriate response to me asking questions regarding means of financing the STS acquisition and how that relates to Syms' involvement in SEVM and DYMH, particularly after reading posts on the SEVM board.
It seemed relevant to me to raise the question why STS (a holding company of SEVM-another Sym company) would accept a 15 million dollar buyout offer in the form of company stock when they have a potential (alleged) valuation of almost 100 million.
Actually I was trying to give the company the benefit of the doubt and not point out the obvious..
Posted by: ERoche Date: Thursday, October 08, 2009 11:22:43 PM
In reply to: iheartmoney who wrote msg# 25363 Post # of 25443
Don't you know you have to establish a known pro position before you can truly and effectively spread doubt. The recent arrival just had to tag in to lend the feminine touch. Probably sitting in the basement with a butt hanging out of her mouth with a wife beater on. I will have to say not a bad job thus far let's see how they do. The positive vibes were drowning out the naysayers had to bring in the cavalry.
If they've received a contract as a subcontracter, then yes 10% would be generous.. Time will tell what the involvement of EVRM is, if anything. I hope for everyone here that this is legitimate, but it's becoming more and more questionable to me, particularly with the frenzy of attacks we seem to be under for raising questions. I think it's obvious to anyone who checks my history that I'm not really a big poster here on IHUB (or anywhere), just trying to do some DD to see if this is worth buying back into or if it is just a scam pumped by multi-aliases on a message board..like so many pink sheet stocks appear to be.
Hi Smooth, I'd suggest if you have questions about the contracts call the Investor Relations Dept. at Stanley, HP, or Honeywell and ask about EVRM's involvement. I'd imagine they'd be able to fill you in on the details. Please post what you find if you do ;)
Good luck everyone.
I commend Somooth for raising the sort of questions that any intelligent investor should raise when doing his DD.. While the IBOX looks great, it doesn't necessarily answer all questions and there seems to be a suprising lack of information available on the web, with the exception of prs put out by EVRM. Considering the magnitude of the contracts, one would expect that others would have taken notice particularly when the contracts (apparently) involve big-time players like Stanley and HP.
I think considering how easy it is for a pink sheet company to just start up (with say a 20k checking acccount) and generate fradulent prs as a means to generate cash by issuing and selling shares, that it's prudent for an investor to try to verify facts. I would think any intelligent investor would appreciate this sort of dialogue, no?
Thanks for the link...
"the total cost of this acquisition is about $15 million in stock and cash. What we are buying is an asset that is worth about $80-$100 million"
I wonder why SEVM (the holding company of STS) would accept an offer ($15 million dollars worth of shares in a company with no assets and zero revenue) considering their apparent valuation of almost $100 million.
It looks like people on the SEVM board claim that the 2 companies shared the same CEO at the time.. Does anyone know if that's accurate? Also, the earliest posts on this board are for a company called Dynamic Media (DYMH), does anyone know (off-hand) when the name changed occured?
Thanks so much for all your help ;)
I was just curious if anyone knows how Evermedia financed its acquisition of STS? According to their most recent filing, finances seem kind of tight..It seems unusual that a company with $0 in revenue would be able to purchase a company with multi-million dollar contracts already lined up.
http://pinksheets.com/otciq/ajax/showFinancialReportById.pdf?id=23456
You guys are too convincing; I had to buy in ;)
Dyax Announces Completion of Common Stock Offering
Press Release
Source: Dyax Corp.
On Monday October 5, 2009, 4:16 pm EDT
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX - News) today announced the completion of the public offering of 5,500,000 shares of its common stock. The net proceeds to Dyax from the sale of shares in this offering, after deducting underwriting discounts and commissions and other estimated offering expenses, were approximately $20.5 million. Dyax intends to use the net proceeds from the offering to fund the development and commercialization of DX-88, the Company’s ongoing research and preclinical activities, and for general corporate purposes.
Jefferies & Company, Inc. acted as sole book-running manager in this offering.
Vaccines Become Hot Property For Big Pharma
8:40 am
September 29, 2009
comments (2)
Recommend (0)
By Scott Hensley
After years of beating a retreat from making vaccines, the world's biggest drug companies are piling back in.
Vaccines are giving the drug business a shot in the arm. (Thierry Zoccolan/Getty Images)
The Wall Street Journal takes a look at three deals Monday that show the business of making vaccines has become hot again. Johnson & Johnson, for instance, agreed to pay $441 million for a stake in Crucell, a Dutch biotech firm, in a deal to collaborate on a single vaccine against all kinds of flu and some other projects.
Many drugmakers turned their backs on the most common vaccines, such as flu shots, after years of low profits and worries about lawsuits. Wyeth gave up making flu vaccine in 2002, after losing money in four of the preceding five years on the business.
The exodus of companies from the flu business left the US dependent on two companies for its supply of flu shots a few years ago. When one of those suppliers ran into problems at its main factory in 2004, the US experienced the worst shortage of flu vaccine in history.
But the big push for swine flu vaccine as well as a slowdown in the traditional business of making drugs has several companies reconsidering their bets. Merck, never abandoned vaccines, but hadn't been selling a flu vaccine. Merck made a deal to market Australian vaccine-maker CSL's seasonal flu vaccine in the US starting next year.
Most of the US companies that stayed in the vaccine business have emphasized high-priced vaccines against serious illnesses, such as Merck's Gardasil, against cervical cancer.
The revival of interest in vaccines isn't exactly philanthropic. "If you have a new vaccine for a new type of meningitis or swine flu, that clearly is a major public-health issue and, therefore, the willingness to pay is going to be greater," said Murray Aitken, a senior vice president at IMS Health told the Journal.
categories: Vaccines
Apparently it's become very difficult to borrow AGEN shares for shorting. The author of this blog was offered 20% interest to lend his AGEN shares to another brokerage house.
http://seekingalpha.com/instablog/383010-chinook-traveler/29041-are-agen-cvm-onty-sqnm-nvax-oncy-and-xoma-being-targeted
This may have already been posted, but there seems to be a lot of institutional buying going on lately:
http://data.cnbc.com/quotes/HEB/tab/8
http://www.mffais.com/heb
Is there some news out from Japan?
I don't know; I hadn't heard about an upgrade..
I think you're right. Yesterday was hectic, but I would think most people, who wanted to, were able to sell, with the volume being so high. Hopefully a lot of them will be wanting to get back in today.
Congratulations Everyone, good news :)
Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial
8:00 am ET 09/21/2009- PR Newswire
ROCKVILLE, Md., Sept. 21 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE Amex: CUR) today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to commence a Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells.
(Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO )
Neuralstem is the first company to commence a stem cell trial to treat ALS. The trial will study the safety of Neuralstem's cells and the surgical procedures and devices required for multiple injections of Neuralstem's cells directly into the grey matter of the spinal cord. The FDA's approval represents a significant step toward delivering regenerative medicine directly to damaged neural cells in humans. ALS affects roughly 30,000 people in the U.S., with about 7,000 new diagnoses per year.
Neuralstem CEO and President, Richard Garr, stated, "The beginning of our clinical trial program is a major step towards achieving Neuralstem's goal of treating ALS, a fatal neurodegenerative disease for which currently there is no effective treatment or cure. While this trial aims to primarily establish safety and feasibility data in treating ALS patients, we also hope to be able to measure a slowing down of the ALS degenerative process. This trial will be in the extremely capable hands of Dr. Eva L. Feldman, M.D., Ph.D., Director of the University of Michigan Health System ALS Clinic and the Program for Neurology Research & Discovery, and Dr. Jonathan Glass, Director of the Emory Neuromuscular Laboratory and Director of the Emory ALS Center, world-renowned for their study and treatment of ALS patients. We believe that there is no better team to conduct this study for us," said Garr. Their participation is subject to formal IRB approval by their institutions.
"We are very excited about this clinical trial," said Dr. Eva L. Feldman, who will direct the Neuralstem clinical trial program for ALS. "This is a major advancement in what still could be a long road to a new and improved treatment for ALS. ALS is a terrible disease that ultimately kills by paralysis," said Feldman, who also directs the A. Alfred Taubman Medical Research Institute. "In work with animals, these spinal cord stem cells both protected at-risk motor neurons and made connections to the neurons controlling muscles. We don't want to raise expectations unduly, but we believe these stem cells could produce similar results in patients with ALS," Dr. Feldman concluded.
About the Trial
The ALS patients will be treated through spinal injections of its patented human neural stem cells.
This first trial, which will primarily evaluate safety of the cells and the surgery procedure, will ultimately consist of 18 ALS patients with varying degrees of the disease. The FDA has approved the first stage of the trial, which consists of 12 patients who will receive five-to-ten stem cell injections in the lumbar area of the spinal cord. The patients will be examined at regular intervals post-surgery, with final review of the data to come about 24 months later.
Neuralstem expects to conduct the trial at Emory University with Dr. Jonathan Glass, M.D., Director of the Emory Neuromuscular Laboratory and Director of the Emory ALS Center, as site Principal Investigator (PI) and with Dr. Nicholas Boulis, M. D. performing the neurosurgery. The overall PI for the ALS trial program is Dr. Eva Feldman, M.D., Ph.D., Director of the University of Michigan Health System ALS Clinic and the Program for Neurology Research & Discovery.
About Neuralstem, Inc.
Neuralstem's patented technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. The company is targeting major central nervous system diseases including: Ischemic Spastic Paraplegia, Traumatic Spinal Cord Injury, Huntington's disease and Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig's disease. Neuralstem plans to initiate a Phase I clinical trial to treat ALS with its stem cells. ALS is a progressive fatal neurodegenerative disease that affects nerve cells in the brain, leading to the degeneration and death of the motor neurons in the spinal cord that control muscle movement. Pre-clinical work has shown Neuralstem's cells to extend the life of rats with ALS (as reported the journal TRANSPLANTATION, October 16, 2006, in collaboration with Johns Hopkins University researchers), and also reversed paralysis in rats with Ischemic Spastic Paraplegia, (as reported in NEUROSCIENCE, June 29, 2007, in collaboration with researchers at University of California San Diego).
Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward- looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10-K for the year ended December 31, 2008 and the quarterly report on form 10-Q for the period ended June 30, 2009.
SOURCE Neuralstem, Inc.
.Ratings Summary
Schwab Equity Rating
Rating as of 09/18/2009
Schwab Equity Ratings Report®
.Credit Suisse Research
No rating provided by Credit Suisse Research
Ned Davis Research
No rating provided by Ned Davis
Argus 12 Month Rating
No rating provided by Argus
Standard & Poor's Opinion
No rating provided by Standard & Poor's
Reuters Research Average Rating
No rating provided by Reuters
Market Edge Second Opinion® Weekly
No rating provided by Market Edge
....Data source identification
It looks like somebody wants in before the end of day ;)
It looks like not too many people are willing to sell at this level..
Me too :)
Apparently at the conference last week HEB presented data comparing Alferon to Relenza. I haven't listened, but here's what it said in the press release:
Comparative analysis will be presented on Alferon(R) LDO (an investigational biologic) versus a present standard of clinical care for both seasonal and pandemic influenza utilizing a monkey (macaque) model system. Both products (Alferon(R) LDO and a neuraminidase inhibitor, Relenza(R)) have been evaluated under similar test conditions by third party, independent researchers. The magnitude of lung protection with each product will be discussed at different concentration ranges.
http://www.marketwatch.com/story/hemispherx-biopharma-presents-at-the-rodman-healthcare-conference-2009-09-02
Volume is already over 1 million..
I don't know, but I would think it should already have a market cap a lot higher than 50 million. Also, it seems to go up easily since it's not very heavily traded. I think once an announcement is made about the FDA having approved the trial it should receive a good deal of press; people right now seem to be unaware of the potential of what they're planning to do.
Another high volume day today (relatively) of 657,226..
This probably doesn't mean much, but it looks like HHS is planning another meeting of the Chronic Fatigue Syndrome Advisory Committee on 10/29 and 10/30 that will be open to the public:
http://edocket.access.gpo.gov/2009/E9-21334.htm
Apparently at the last meeting in May Ampligen was brought up a few times:
http://www.hhs.gov/advcomcfs/meetings/minutes/cfsac20081028min.pdf
I think this is the new short data that came out last night:
http://shortsqueeze.com/?symbol=agen
Trading really slowed down since the announcement.. I would have thought it would be good for the stock price at least short-term. Bashers on other boards had been using the issuance to try to warn people of dilution.
Hemispherx Biopharma Announces Cancellation Of Adjourned Stockholders' Meeting
9:01 am ET 09/02/2009- Dow Jones
(MORE TO FOLLOW) Dow Jones Newswires (212-416-2400)
09-02-09 0901ET
Copyright (c) 2009 Dow Jones & Company, Inc.
Some people (mainly institutions and banks) are allowed to trade as early as 4 a.m.
http://en.wikipedia.org/wiki/Extended_hours_trading